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INTRODUCTION
Endoscopic retrograde cholangiopancreatography (ERCP) has 
become the first-choice treatment for common bile duct 
(CBD) disorders and periampullary disease.1,2 Compared with 
other endoscopic examinations, ERCP carries a higher poten-
tial for complications, ranging from minor events with prompt 
resolution, such as mild pancreatitis, to major life-threatening 
risks, such as hemorrhage and severe pancreatitis.3-7 In previ-
ous studies, the risk factors for bleeding as a result of ERCP are 
coagulopathy, liver cirrhosis, renal failure, sphincterotomy, 
and papillectomy.8-10 In particular, patients with liver cirrhosis 
have been considered to be at high risk for ERCP-related bleed-
ing.11,12 Cirrhosis-associated coagulopathy, liver dysfunction, 
and gastroesophageal varices may increase the risk of proce-
dure-related bleeding in these patients.4 
To date, several studies have analyzed the risk of ERCP in 
patients with liver cirrhosis.11,13-15 However, previous studies re-
ported limited sample sizes,12,15,16 small portions of therapeutic 
ERCPs,14 limited information about the type of procedure or 
degree of cirrhosis, and substantial heterogeneity in the com-
parison group.11,12 Furthermore, the safety of ERCP in liver cir-
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rhosis is still controversial because of limited data.11,14 Adler, et 
al.14 reported that therapeutic ERCP is safe and effective in pa-
tients with liver cirrhosis. Meanwhile, however, Inamdar, et 
al.11 showed that the frequency of ERCP-related bleeding was 
statistically significant in patients with decompensated liver cir-
rhosis. Endoscopic sphincterotomy (EST) or balloon dilatation, 
which means cutting or dilatation of the sphincter muscle that 
lies at the juncture of the intestine with the bile ducts, is an es-
sential technique in patients who receive ERCP.16-18 Prior to those 
procedures in cirrhotic patients, recognition and understand-
ing of the potential complications of ERCP are important for 
appropriate patient selection for performing ERCP. 
Here, we aimed to investigate the safety of ERCP in patients 
with liver cirrhosis, focusing on bleeding complications. For 
the evaluation of bleeding complications of ERCP in patients 
with cirrhosis, we performed propensity-score matched analy-
sis using a retrospective cohort data.  
MATERIALS AND METHODS
Patients
A total of 8554 patients had undergone ERCP at an academic 
tertiary hospital in South Korea between January 2005 and De-
cember 2015. Among them, 555 patients were excluded accord-
ing to the following exclusion criteria: ERCP for bile duct anas-
tomosis site stricture after liver transplantation in the cirrhotic 
group (n=129); failed cannulation during the procedure (n= 
269); only cholangiography without insertion of a guidewire 
during the procedure (n=93); and papillectomy (n=64). Finally, 
264 patients with cirrhosis and 7735 patients without cirrhosis 
remained.
The demographic, clinical, and laboratory data of the study 
population were collected from medical records. Medical re-
cord data, including sex, age at the time of procedure, etiology of 
cirrhosis, cardiovascular disease, medication related to bleeding 
tendency, pre-procedure laboratory values, Child-Pugh (CP) 
scores at the time of the procedure, ERCP indications, proce-
dural details, and procedure-related adverse events, were re-
viewed. Liver cirrhosis was diagnosed according to laboratory 
values, liver biopsies, and the results of imaging studies. If liver 
histologic information was not available, clinically diagnosed 
liver cirrhosis was based on following criteria: 1) platelet count 
of <100000/µL and ultrasonographic findings suggestive of 
cirrhosis, including a blunted, nodular liver edge accompa-
nied by splenomegaly (>12 cm); 2) esophageal or gastric vari-
ces; or 3) overt complications of liver cirrhosis, including asci-
tes, variceal bleeding, and hepatic encephalopathy.19 The 
severity of liver cirrhosis was classified according to CP class. 
This study was performed in accordance with ethical guide-
lines of the 1975 Declaration of Helsinki and approved by the 
Institutional Review Board of Severance Hospital (IRB num-
ber: 4-2016-1090).
Propensity score matching
Propensity score matching was introduced to reduce patient 
selection bias and the potential confounding biases due to 
differences between the two patient groups. A biostatistician 
in the Medical Research Collaborating Center matched the 
group of the patients with liver cirrhosis to the group of those 
without liver cirrhosis at a 1:3 ratio using the calculated pro-
pensity score by optimal matching methods. To eliminate bias 
caused by different baseline characteristics, we calculated 
propensity score based on age and sex. After optimal match-
ing, we compared the baseline characteristics. Finally, 768 pa-
tients were matched, including 192 patients in the cirrhotic 
group and 576 patients in the non-cirrhotic group (Fig. 1). 
Endoscopic procedure
Patients were sedated with intravenous anesthesia (midazol-
am and/or propofol), along with continuous monitoring of 
blood pressure, heart rate, and oxygen saturation. All patients 
received intravenous cimetropium bromide for inhibiting duo-
denal spasm. A side-viewing duodenal scope (TJF-260; Olym-
pus, Tokyo, Japan) was used for ERCP. After the papilla had 
been examined with the endoscope, selective cannulation of 
either the CBD or the ventral pancreatic duct was performed. 
Once the chosen duct was selectively cannulated, either a 
cholangiogram or a pancreatogram was obtained fluoroscopi-
cally with injection of contrast medium into the duct. Four 
hours after the ERCP and at 5 a.m. of the next day of the proce-
dure, blood chemistry, including serum amylase, lipase, and 
total bilirubin level; chest radiography; and simple abdominal 
radiography were performed for evaluating post-ERCP pan-
creatitis (PEP), cholangitis, and bowel perforation. To identify 
post-ERCP bleeding, hemoglobin level and bleeding history 
were checked. Most of the patients taking medications related 
to bleeding tendency (such as aspirin, warfarin, clopidogrel, 
Fig. 1. Flow diagram of patient selection. ERCP, endoscopic retrograde 
cholangiopancreatography.
8554 patients had undergone ERCP between January 2005 and December 2015
264 patients with cirrhosis
192 patients with cirrhosis
7735 patients without cirrhosis
Excluded (n=555)
•  Indication of ERCP for anastomosis site 
stricture after liver transplantation (n=129)
•  Failed cannulation (n=269)
•  Only cholangiography (n=93)
•  Papillectomy (n=64)
Propensity score matching 1:3
576 patients without cirrhosis
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or a new oral anticoagulant) needed to stop the medications 
for at least until 3 days before the procedure.
Definition and management of complications
Post-sphincterotomy bleeding was defined as immediate 
bleeding requiring endoscopic or other intervention within 24 
hr or delayed bleeding recognized on the basis of clinical evi-
dence (such as melena, hematochezia, and hematemesis), with 
a decrease in hemoglobin level >2 g/dL or the need for blood 
transfusion within 10 days after ERCP.4 Clinically significant 
bleeding and its severity were classified as follows: mild bleed-
ing was defined as overt bleeding with a decrease of hemoglo-
bin level <3 g/dL, without the need for transfusion; moderate 
bleeding was defined as blood transfusion of 4 units or less 
without the need for angiographic intervention or surgery; and 
severe bleeding was defined as blood transfusion of 5 units or 
more or the need for angiographic or surgical intervention.20
Statistical analysis
Statistical analyses were performed using SPSS software (ver-
sion 20.0; IBM Corp., Armonk, NY, USA). Associations involv-
ing parametric data were assessed using Student’s t-test. Chi-
square (χ2) test was used to compare categorical data, and 
Student’s t-test was used to compare continuous data. Statisti-
cal analysis was performed with the Jonckheere-Terpstra test 
to determine whether there was a statistically significant trend 
among independent samples. All two-tailed p values of <0.05 
were considered statistically significant.
RESULTS
Patients
After propensity score matching, a total of 192 patients with cir-
rhosis (age 59.4±9.5 years) were included in the analysis. The 
etiologies of cirrhosis were as follows: hepatitis B (n=106, 
59.2%), hepatitis C (n=21, 11.7%), and alcoholic (n=28, 15.6%). 
Among 192 patients with liver cirrhosis, 92 (47.9%) had CP 
classification A, 55 (28.6%) had CP classification B, and 45 
(23.4%) had CP classification C. The patient demographic and 
procedure characteristics are summarized in Table 1. The indi-
cations for ERCP were as follows: CBD stone with or without 
acute cholangitis (n=296, 38.5%), bile duct obstruction 
(n=335, 43.6%), and pancreatitis (n=32, 4.2%). 
ERCP-related bleeding complications
A total of 48 patients had post-ERCP bleeding among the en-
rolled patients, and there was a statistically significantly higher 
rate of bleeding complication in patients with cirrhosis (10.9% 
vs. 4.7%; p=0.003). Among the bleeding cases, 32 patients (66.7%) 
had mild post-ERCP bleeding; 16 patients (33.3%) had mod-
erate post-ERCP bleeding (Table 2). Most bleeding events (n= 
32, 66.7%) were mild oozing that occurred during the proce-
dure. No cases of massive bleeding occurred. Thirty-two 
bleeding episodes were controlled with electrical cauteriza-
tion with a needle knife and/or hemoclip. No cases needed 
embolization or surgical management. There was no event of 
mortality related to bleeding. 
Risk factors related to post-ERCP bleeding
Univariate analysis showed liver cirrhosis to be a significant 
risk factor related to post-ERCP bleeding (p=0.003). Because 
Table 1. Patient Baseline Characteristics
Variables
Total
(n=768)
Cirrhotic
(n=192)
Non-cirrhotic
(n=576)
p 
value
Patient related variables
Male 592 (77.1) 148 (77.1) 444 (77.1) 1.000
Age (yr) 59.4±9.5 59.4±9.5 59.4±9.5 1.000
Body mass index 22.6±3.5 22.6±3.5 22.7±3.5 0.702
Prothrombin time (INR) 1.01±0.21 1.08±0.23 0.98±0.20 0.001 
Platelet (×103/µL) 210.8±96.8 147.4±77.4 231.9±93.3 0.001 
Cardiovascular disease 52 (6.8) 11 (5.7) 41 (7.1) 0.619
CKD 29 (3.8) 17 (8.9) 12 (2.1) 0.001
Anticoagulant drug 89 (11.6) 27 (14.1) 62 (10.8) 0.241
Procedure related variables
Indication of ERCP
CBD stone 296 (38.5) 71 (37.0) 225 (39.1) 0.669 
Bile duct obstruction 335 (43.6) 98 (51.0) 237 (41.1) 0.019 
Pancreatitis 32 (4.2) 3 (1.6) 29 (5.0) 0.037 
Procedure type
Stent insertion ERBD 250 (32.6) 63 (32.8) 187 (32.5) 0.929
EST 350 (45.6) 93 (48.4) 257 (44.6) 0.359
Ballooning (EPBD) 52 (6.8) 14 (7.3) 38 (6.6) 0.741
ERCP, endoscopic retrograde cholangiopancreatography; ERBD, endoscopic 
retrograde biliary drainage; EST, endoscopic sphincterotomy; EPBD, endoscop-
ic papillary balloon dilation; INR, international normalized ratio; CKD, chronic 
kidney disease; CBD, common bile duct.
Variables are expressed as mean±standard deviation or n (%).
Table 2. Comparison of Post-ERCP Bleeding between Patients with Cir-
rhosis and Those without Cirrhosis
Adverse event
Total
(n=768)
Cirrhotic
(n=192)
Non-cirrhotic
(n=576)
p value
Bleeding 48 (6.3) 21 (10.9) 27 (4.7) 0.003
Severity 0.555
Mild 32 (66.7) 13 (61.9) 19 (70.4)
Moderate 16 (33.3) 8 (38.1) 8 (29.6)
Severe 0 (0.0) 0 (0.0) 0 (0.0)
Time of bleeding 0.712
Immediate 39 (81.3) 18 (85.7) 21 (77.8)
Delayed 9 (18.8) 3 (14.3) 6 (22.2)
Treatment modality 0.758
Conservative 16 (33.3) 6 (28.6) 10 (37.0)
Endoscopic 32 (66.7) 15 (71.4) 17 (63.0)
ERCP, endoscopic retrograde cholangiopancreatography.
Variables are expressed as n (%).
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cirrhosis associated coagulopathy may increase the risk of 
procedure-related bleeding, we performed additional multi-
variate analysis. Liver cirrhosis was identified as an indepen-
dent risk factor related to post-ERCP bleeding after adjustment 
for prothrombin time and duration of ERCP (p=0.003) (Table 3). 
Procedure types were not independent risk factors for post-
ERCP bleeding.
Bleeding complications according to the CP 
classification
In subgroup analysis, there was a significant difference in the 
rate of post-procedure bleeding among patients with different 
CP classifications (Table 4). In multivariate analysis, CP class 
C was found to be associated with an increased incidence of 
post-ERCP bleeding in patients with cirrhosis (odds ratio 6.144, 
95% confidence interval 1.320–28.606; p=0.021).
Complications according to procedure type
The patients underwent various therapeutic maneuvers dur-
ing ERCP, which were individualized based on indications and 
intraprocedural findings. Among patients with liver cirrhosis, 
93 patients (48.4%) underwent EST; however, there was no sig-
nificant difference in the rate of post-ERCP bleeding in patients 
who underwent biliary sphincterotomy, compared with those 
who did not have a sphincterotomy (10.8% vs. 11.1%, p=0.561) 
(Supplementary Table 1, only online). We further analyzed 
the events of PEP and cholangitis because a high frequency of 
adverse events, including PEP and cholangitis, occurred in 
patients with cirrhosis undergoing ERCP. In the present study, 
there were no significant differences in the occurrences of PEP 
and cholangitis (p=0.507 and p=0.489) between the cirrhotic 
and non-cirrhotic groups (Supplementary Table 2, only on-
line). In multivariate analysis, stent insertion was found to be 
associated with increased incidences of PEP and cholangitis 
(p=0.005 and p=0.029) (Supplementary Tables 3 and 4, only 
online).
DISCUSSION
In this study, we analyzed our data after propensity score match-
ing according to identified variables including sex and age. 
We confirmed that patients with liver cirrhosis face a greater 
risk of experiencing post-ERCP bleeding: liver cirrhosis was an 
independent risk factor associated with post-ERCP bleeding. 
These results were not changed after further adjustment for 
duration of ERCP, procedure type, and prothrombin time. 
Patients with liver cirrhosis are predisposed to developing 
underlying coagulopathy. Because of poor hepatic synthetic 
function, these patients have coagulation disorders and low 
platelet counts, which are risk factors of post-procedure bleed-
ing. Zhang, et al.15 reported that post-ERCP bleeding was in-
creased in patients with Model for End-stage Liver Disease 
(MELD) scores >11.5. Similar to previous studies, patients with 
CP class C cirrhosis experienced significantly more bleeding 
than those with CP class A or B in this study. 
ERCP with sphincterotomy has been considered to pose a 
higher risk for post-procedure bleeding.4 In a previous study, 
complications of EST occur in about 10% of patients, and 2–3% 
may have a prolonged hospital stay.20 The presence of varices, 
which can develop in the duodenum in patients with cirrhosis, 
may increase the risk of bleeding after sphincterotomy. How-
ever, in this study, bleeding risk after sphincterotomy did not 
show any statistically significant difference from the patients 
with cirrhosis, compared to those without cirrhosis. Regardless 
of the sphincterotomy, due to a tendency for patients with cir-
rhosis to bleed, bleeding complications of ERCP are consid-
ered to occur. Accordingly, the rate of bleeding was higher in 
patients with cirrhosis in this study. 
Mariante-Neto, et al.21 and Romano, et al.22 reported that 
lower levels of creatinine may influence the low prognostic 
value of MELD score, which is associated post-ERCP bleed-
Table 4. Multivariate Analysis of Risk Factors for Post-ERCP Bleeding in 
Cirrhotic Patients
Variables
Multivariate
Adjusted OR 95% CI p value
Child-Pugh class 
A 1
B 2.533 0.704–9.112 0.155
C 6.144 1.320–28.606 0.021
Albumin 0.539 0.156–1.867 0.330
Platelet 0.987 0.976–0.999 0.032
CKD 4.757 0.525–43.109 0.165
Anticoagulant drugs 1.690 0.257–11.116 0.585
EST 1.760 0.533–5.817 0.354
EPBD 0.552 0.052–5.889 0.623
ERCP, endoscopic retrograde cholangiopancreatography; OR, odds ratio; CI, 
confidence interval; CKD, chronic kidney disease; EST, endoscopic sphincterot-
omy; EPBD, endoscopic papillary balloon dilatation. 
Table 3. Univariate and Multivariate Analysis of Risk Factors for Post-
ERCP Bleeding
Variables
Univariate Multivariate
p value Adjusted OR 95% CI p value
Liver cirrhosis 0.003 2.497 1.377–4.530 0.003
Prothrombin time  
  (INR)
0.800 1.198 0.298–4.819 0.799
EST 0.871
EPBD 0.316
Antiplatelet/ 
  coagulant
0.399
Duration of ERCP 0.158 1.013 0.997–1.029 0.103
Stent insertion 0.293
ERCP, endoscopic retrograde cholangiopancreatography; OR, odds ratio; CI, 
confidence interval; INR, international normalized ratio; EST, endoscopic 
sphincterotomy; EPBD, endoscopic papillary balloon dilatation.
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ing, and suggested that sex may have an impact on the prog-
nostic value of both MELD and CP scores. Herein, we matched 
all patients by age and sex. We analyzed the impact of liver 
cirrhosis on post-ERCP bleeding both without adjustment for 
platelet/prothrombin time and with it. After all of this, regardless 
of platelet/prothrombin time, liver cirrhosis was a significant 
risk factor in this study. 
Our study has several limitations. First, the retrospective 
nature may lead to an inherent selection bias. To overcome 
this limitation, we performed propensity score matching. This 
study is based on a cohort from large representative tertiary 
referral hospitals. Further, we performed additional adjust-
ment for platelet, albumin, and prothrombin time to reduce 
the selection bias. After matching, more than 50% of therapeu-
tic ERCPs was performed in this study, and degree of cirrhosis 
was analyzed. Second, the definition of bleeding events has 
not been standardized in previous studies.11,13-15,23,24 The num-
ber of post-ERCP bleedings may depend on the definition of 
bleeding associated with a procedure. In this study, we catego-
rized the bleeding grade according to the clinical and laborato-
ry findings to find the effect of ERCP in patients with cirrhosis. 
In conclusion, the incidence of post-ERCP bleeding in pa-
tients with liver cirrhosis is remarkably high after diagnostic 
and therapeutic ERCP. CP classification can be a valuable pre-
dictive factor for ERCP-related adverse events, especially in 
terms of bleeding. Bleeding problems may be related to the 
formation of a powerful collateral vascular bed in the area of 
the duodenum due to portal hypertension. In this regard, ther-
apeutic ERCP in patients with liver cirrhosis should be used 
according to absolute indications and with high caution. For 
diagnostic purposes, minimally invasive methods, such as mag-
netic resonance cholangiopancreatography, endoscopic ultra-
sound, etc., may be more appropriate.
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